Allogeneic BCMA-Targeting CAR-T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 Universal Trial Interim Results

Allogeneic BCMA-Targeting CAR-T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 Universal Trial Interim Results

header-info

We evaluated escalating doses of ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial.